🟢 BioXcel Therapeutics is trading 6.25% up in pre-market after Q2 earnings beat and positive SERENITY At-Home data

BioXcel Therapeutics is trading at $0.85 (+6.25%) after recent positive Q2 2026 earnings and reinforced confidence from late-stage SERENITY At-Home data. - The company reported Q2 2026 EPS of -$0.49 on August 12, 2026, beating analyst estimates of -$0.56. - The FDA accepted BioXcel’s supplemental application for at-home use with a November 14, 2026, decision date. - Investors continue to monitor the company’s financing and lender obligations, including a recent August 21, 2026, refinancing deadline.